Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.50 USD

29.50
26,896,912

+0.40 (1.37%)

Updated Jul 16, 2024 04:01 PM ET

Pre-Market: $29.35 -0.15 (-0.51%) 8:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Parth Panchal headshot

Allergan To Acquire ZELTIQ in $2.47 Billion Deal, ZELTIQ Shares Pop 13%

Pharmaceutical giant Allergan (AGN) announced on Monday they will acquire ZELTIQ Aesthetics (ZLTQ) in a $2.47 billion deal.

    Drug Stocks Earnings Slated for Feb 14: INCY, PRTA & More

    The year 2017 seems to have started on a positive note for investors in the U.S. Approximately 71.6% of the companies (or 358 members) in the S&P 500 Index have reported results so far.

      Sheraz Mian headshot

      Q4 Scorecard & Analyst Reports for Pfizer, Boeing & Goldman Sachs

      Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), Pfizer (PFE) and Goldman Sachs (GS).

        Model N (MODN) Q1 Loss Narrower than Expected, Guides Well

        Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.

          ARIAD Files for EU Approval of Lung Cancer Drug Brigatinib

          ARIAD Pharmaceuticals, Inc. (ARIA) announced the submission of a Marketing Authorisation Application (MAA) for its experimental ALK inhibitor, brigatinib, with the European Medicines Agency (EMA).

            Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)

            Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.

              Sweta Killa headshot

              Q4 Earnings Faring Well for Pharma ETFs

              Despite the fact that the industry primes posted mixed results, the stocks witnessed smooth trading following their results.

                Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

                Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.

                  Portola, HealthCare Royalty Partners Ink $150 Million Deal

                  Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.

                    Merck???s Keytruda Gets Priority Review for Bladder Cancer

                    Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

                      Swarup Gupta headshot

                      Dow 30 Stock Roundup: Apple, Intel, Exxon Beat; Merck, Pfizer, Chevron Miss on Revenues

                      The Dow suffered losses over the week as optimism over Trump's election gave way to apprehension over his actions as President.

                        Arpita Dutt headshot

                        Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

                        Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

                          Agilent (A) Announces Expanded Use of Diagnostic Assay

                          Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.

                            Merck (MRK) Tops Q4 Earnings; Pharmaceutical Sales Down

                            Merck & Co., Inc. (MRK) reported fourth-quarter 2016 earnings of 89 cents per share, which beat the Zacks Consensus Estimate of 88 cents by a penny.

                              Drug Stocks to Report Q4 Earnings on Feb 2: MRK & AMGN

                              How will these two drug stocks, MRK & AMGN, which are both scheduled to report Q4 results on Feb 2, fare this earnings season?

                                Merck Keytruda Gets EU Approval for First-Line Lung Cancer

                                Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

                                  SanofiRegeneron Sarilumab Approved in Canada for Arthritis

                                  Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

                                    Mark Vickery headshot

                                    Trade War Concerns Coming Home to Roost

                                    It hadn't been priced in at all during the Trump Rally, but now fears of a trade war with China and Mexico are being actualized.

                                      Kinjel Shah headshot

                                      Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft

                                      Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.

                                        Pfizer (PFE) Misses on Q4 Earnings; Tops Sales Estimate

                                        PFE missed fourth quarter earnings which came in at 47 cents while our consensus called for EPS of 50 cents.

                                          Pfizer (PFE) Gets Positive CHMP Opinion for Arthritis Drug

                                          Pfizer Inc. (PFE) announced that Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for the company's marketing authorisation application (MAA) for its rheumatoid arthritis (RA) drug, Xeljanz.

                                            Drug Stocks Reporting Q4 Earnings on Jan 31: LLY and PFE

                                            Two pharma giants - Pfizer and Lilly - are set to report fourth-quarter results on Jan 31. Let's see how things are shaping up for this quarter.

                                              Pfizer (PFE) C. Difficile Vaccine Positive in Phase II Study

                                              Pfizer Inc. (PFE) announced positive top-line results from a phase II study on its investigational vaccine candidate, PF-06425090, for the prevention of clostridium difficile infection.

                                                Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?

                                                We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.

                                                  Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                                                  We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.